Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70145 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Merete Dam und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Antineoplastic Agents, Asparaginase, Polyethylene Glycols, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Health Research Foundation of Central Denmark Region, Barncancerfonden, Ølufgaard Foundation.
Abstract (Originalsprache)
Polyethylene glycol (peg)‐asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg‐asparaginase. The study, covering 644 patients aged 1–45 with ALL under the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 Protocol (February 2017–December 2022, in Nordic and Baltic countries), included 3003 AEA samples. Sampling occurred 14 days post peg‐asparaginase doses, with additional sampling between doses. The incidence of inactivation was 15.2%. Utilizing the pharmacokinetic model, estimates revealed an 87.8% sensitivity and 65.5% specificity for detecting increased peg‐asparaginase clearance over time in patients experiencing inactivation. Identification of increased clearance preceding inactivation in the NOPHO ALL2008 dataset highlights the potential of pharmacokinetic sampling to predict inactivation and enable timely intervention before clinical manifestation, with further refinement and inclusion of additional protocols into a unified model offering the promise of improving clinicians' ability to assess individual patient risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Paediatric Haematology and Oncology, Oslo University Hospital, Oslo, Norway.
- Tallinn Children's Hospital, Tallinn, Estonia.
ORCID-Profile: Merete Dam
Förderung
- The Health Research Foundation of Central Denmark Region
- Barncancerfonden
- Ølufgaard Foundation
- Lizzy and Mogens Staal Foundation
- Børnecancerfonden
- Brogaard Foundation
Zitieren
APA
Dam, M., Centanni, M., Centanni, D., Friberg, L. E., Karlsson, M. O., Lynggaard, L. S., Johannsdottir, I. M., Lepik, K., Vaitkeviciene, G. E., Griskevicius, L., Pöyhönen, T., Pyörälä, M., Jónsson, Ó. G., Quist-Paulsen, P., Schmiegelow, K., Christoforaki, T., Overgaard, U., Hansen, S. N., & Albertsen, B. K. (2025). Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study. British Journal of Haematology. https://doi.org/10.1111/bjh.70145
Vancouver
Dam M, Centanni M, Centanni D, Friberg LE, Karlsson MO, Lynggaard LS, et al. Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study. British Journal of Haematology. 2025. doi:10.1111/bjh.70145
BibTeX
@article{Dam2025,
author = {Dam, Merete and Centanni, Maddalena and Centanni, Daniel and Friberg, Lena E and Karlsson, Mats O and Lynggaard, Line S and Johannsdottir, Inga M and Lepik, Kristi and Vaitkeviciene, Goda E and Griskevicius, Laimonas and Pöyhönen, Tuuli and Pyörälä, Marja and Jónsson, Ólafur G and Quist-Paulsen, Petter and Schmiegelow, Kjeld and Christoforaki, Tania and Overgaard, Ulrik and Hansen, Stefan N and Albertsen, Birgitte K},
title = {Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70145}
}
EUVIMED